Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma

Spyre Therapeutics, Inc.

As of May 29, 2024, common shares outstanding: 50,782,384.
Pro forma shares (incl. Series A & B preferred conversion): ~65.3 million.
Conversion of Series B Preferred was effective per prior 8-K filed May 15, 2024.

item 7.01

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-150395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.